



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Docket Number:  
**01662/50302**

Application Number  
09/714,351

Filing Date  
November 16, 2000

Examiner  
L. Stockton

Art Unit  
1626

Invention Title  
**Polymorphic Form of Atorvastatin Calcium**

Inventors  
Ayalon, et al.

Address to:  
Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450

on  
Date: 1/31/06

Signature: Agnes Xu  
Agnes Xu

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each non-U.S. patent, non-U.S. published application, unpublished U.S. application, non-patent publication, or other information listed on the PTO form 1449 is enclosed.
4. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.
5. Please debit Deposit Account No. **11-0600** in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p) to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached. 37 CFR §1.97(c)(2).

Dated: January 31, 2006

By: Joseph A. Coppola  
Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON LLP  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
**CUSTOMER NO. 26646**

02/03/2006 MBIZUNES 00000045 110600 09714351  
01 FC:1806 180.00 DA



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
1662/50302

SERIAL NO.  
09/714,351

APPLICANT  
Ayalon, et al.

FILING DATE  
November 16, 2000

GROUP  
1626

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		David J. W. Grant, Theory and Origin of Polymorphism, in Drugs of the Pharmaceutical Sciences, vol. 95, Polymorphism in Pharmaceutical Solids, Chapter 1, (Harry G. Brittain ed., 1999)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	